Chris R. Garrett

951 total citations
43 papers, 757 citations indexed

About

Chris R. Garrett is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Chris R. Garrett has authored 43 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Chris R. Garrett's work include Colorectal Cancer Treatments and Studies (22 papers), Cancer Genomics and Diagnostics (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Chris R. Garrett is often cited by papers focused on Colorectal Cancer Treatments and Studies (22 papers), Cancer Genomics and Diagnostics (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Chris R. Garrett collaborates with scholars based in United States, United Kingdom and Canada. Chris R. Garrett's co-authors include Daniel M. Sullivan, Adil Daud, George R. Simon, Pamela N. Münster, Alberto Chiappori, Jade Homsi, Douglas C. Marchion, Elona Biçaku, Richard M. Lush and Morgen Schmitt and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Clinical Cancer Research.

In The Last Decade

Chris R. Garrett

42 papers receiving 738 citations

Peers

Countries citing papers authored by Chris R. Garrett

Since Specialization

Citations

This map shows the geographic impact of Chris R. Garrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris R. Garrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris R. Garrett more than expected).

Fields of papers citing papers by Chris R. Garrett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris R. Garrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris R. Garrett. The network helps show where Chris R. Garrett may publish in the future.

Co-authorship network of co-authors of Chris R. Garrett

This figure shows the co-authorship network connecting the top 25 collaborators of Chris R. Garrett. A scholar is included among the top collaborators of Chris R. Garrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris R. Garrett. Chris R. Garrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Predictors of clonal evolution in metastatic colorectal cancer patients. 2015 ·Journal of Clinical Oncology ·Maria Pia Morelli, Michael J. Overman, Bryan K. Kee, (unknown), Van K. Morris, David R. Fogelman, Filip Jankú, Chris R. Garrett, Imad Shureiqi, Kanwal Raghav, Cathy Eng, (unknown), Robert A. Wolff, Helmy Eltoukhy, Richard B. Lanman, AmirAli Talasaz, Scott Kopetz	1
2	An Aberrant Leukotriene A4 Hydrolase–Proline-Glycine-Proline Pathway in the Pathogenesis of Chronic Obstructive Pulmonary Disease 2014 ·American Journal of Respiratory and Critical Care Medicine ·J. Michael Wells, Philip O’Reilly, Tomasz Szul, (unknown), (unknown), Chris R. Garrett, Carmel M. McNicholas, Mojtaba Abdul Roda, Bruce E. Miller, Ruth Tal‐Singer, Amit Gaggar, Stephen I. Rennard, Patricia L. Jackson, J. Edwin Blalock	50
3	Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). 2014 ·Journal of Clinical Oncology ·Scott Kopetz, Michael J. Overman, Ken Chen, (unknown), Bryan K. Kee, David R. Fogelman, Arvind Dasari, Kanwal Raghav, (unknown), (unknown), Imad Shureiqi, Chris R. Garrett, Robert A. Wolff, Keyur Patel, Kenneth Aldape, Rajyalakshmi Luthra, Mark J. Routbort, Dipen M. Maru, Funda Meric‐Bernstam, Cathy Eng	18
4	Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients. 2014 ·Journal of Clinical Oncology ·Maria Pia Morelli, Michael J. Overman, (unknown), Van K. Morris, Imad Shureiqi, Chris R. Garrett, David R. Fogelman, Kanwal Raghav, Bryan K. Kee, (unknown), Cathy Eng, Robert A. Wolff, Dragan Sebisanovic, (unknown), (unknown), Gangwu Mei, (unknown), Helmy Eltoukhy, AmirAli Talasaz, Scott Kopetz	6
5	Prognostic effect of angiotensin-converting-enzyme inhibitors in HCC patients treated with sorafenib. 2013 ·Journal of Clinical Oncology ·(unknown), Ahmed O. Kaseb, Hesham M. Hassabo, Chris R. Garrett, Jean‐Nicolas Vauthey, (unknown), Manal M. Hassan	1
6	Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure. 2013 ·Journal of Clinical Oncology ·Nishin A. Bhadkamkar, İbrahim Halil Şahin, Yehua Shen, Hesham M. Hassabo, Bryan K. Kee, Manal M. Hassan, Chris R. Garrett	5
7	Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer 2011 ·Cancer Chemotherapy and Pharmacology ·Peter D. Boasberg, Charles H. Redfern, Gregory A. Daniels, David Bodkin, Chris R. Garrett, Alejandro D. Ricart	56
8	Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). 2011 ·Journal of Clinical Oncology ·Hesham M. Hassabo, (unknown), Ben George, (unknown), Veerabhadran Baladandayuthapani, Scott Kopetz, David R. Fogelman, (unknown), Cathy Eng, Chris R. Garrett	4
9	Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. 2010 ·Journal of Clinical Oncology ·Christopher H. Lieu, Robert A. Wolff, Cathy Eng, Michael J. Overman, Linda Henry, (unknown), Chris R. Garrett, J. L. Abbruzzese, Gary E. Gallick, Scott Kopetz	8
10	Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC) 2009 ·Journal of Clinical Oncology ·Shivani Sharma, T. Reid, (unknown), Chris R. Garrett, J. Thaddeus Beck, S.E. Davidson, Mary J. MacKenzie, Ulrike Brandt, J. Randolph Hecht	7
11	A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy 2008 ·Journal of Clinical Oncology ·Chris R. Garrett, Lillian L. Siu, Anthony B. El-Khoueiry, Jan Buter, Caio Rocha‐Lima, J. L. Marshall, Georgia Kollia, (unknown), S. Syed, David Feltquate	13
12	Multicenter phase II study of gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (APC): Final analysis of clinical and quality of life endpoints 2008 ·Journal of Clinical Oncology ·Renuka Iyer, Jingru Yu, Chris R. Garrett, Alan Litwin, Nikhil I. Khushalani, (unknown), Nancy R. Webb, John T. Phelan, Milind Javle	4
13	Melanoma of the Anal Canal: A Case Series 2007 ·Diseases of the Colon & Rectum ·Jade Homsi, Chris R. Garrett	26
14	A case of primary squamous cell colon cancer 2007 ·Journal of Oncology Pharmacy Practice ·(unknown), Chris R. Garrett, Catherine Chodkiewicz	6
15	Phase I trial of a sequence-specific combination of the HDAC inhibitor, valproic acid (VPA), and the topoisomerase II inhibitor, epirubicin, in advanced solid tumors: Clinical results and correlative studies 2006 ·Journal of Clinical Oncology ·Pamela N. Münster, Douglas C. Marchion, Elona Biçaku, Morgen Schmitt, (unknown), Paul R. Stauffer, Chris R. Garrett, Alberto Chiappori, Dan M. Sullivan, Adil Daud	4
16	Imaging Gastrointestinal Stromal Tumors 2005 ·Cancer Control ·Marla R. Hersh, Junsung Choi, Chris R. Garrett, Robert A. Clark	49
17	Targeted Therapies in the Treatment of Colorectal Cancers 2005 ·Cancer Control ·(unknown), Chris R. Garrett	29
18	Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors 2004 ·Journal of Clinical Oncology ·Francisco Robert, Chris R. Garrett, William R. Dinwoodie, Daniel M. Sullivan, Michael W. Bishop, Michael Amantea, (unknown), Steven D. Reich	3
19	A Phase II study of T900607 (T607) in subjects with chemotherapy-naïve unresectable hepatocellular carcinoma (HCC) 2004 ·Journal of Clinical Oncology ·Chris R. Garrett, Carlos Becerra, (unknown), Mohammad Hirmand	1
20	Travel times and radiotherapy uptake in two English counties 1997 ·Public Health ·Paul Cosford, Chris R. Garrett, Katherine Turner	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact